Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Maertens

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Immunology|June 22, 2019
Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 DeficiencyF Queiroz-Telles, T Mercier, J Maertens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2001
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensusS Ascioglu, J H Rex, B de Pauw, et al.
Leukemia|June 8, 2011
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40A W Rijneveld, B van der Holt, S M G J Daenen, et al.
Leukemia|February 24, 2012
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVONS Daenen, B van der Holt, A W Dekker, et al.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Bone Marrow Transplantation|September 22, 2019
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)E González-Barca, A Boumendil, D Blaise, et al.
Bone Marrow Transplantation|September 12, 2017
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working partyC Scheid, L de Wreede, A van Biezen, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Immunology|June 22, 2019
Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 DeficiencyF Queiroz-Telles, T Mercier, J Maertens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2001
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensusS Ascioglu, J H Rex, B de Pauw, et al.
Leukemia|June 8, 2011
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40A W Rijneveld, B van der Holt, S M G J Daenen, et al.
Leukemia|February 24, 2012
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVONS Daenen, B van der Holt, A W Dekker, et al.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Bone Marrow Transplantation|September 22, 2019
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)E González-Barca, A Boumendil, D Blaise, et al.
Bone Marrow Transplantation|September 12, 2017
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working partyC Scheid, L de Wreede, A van Biezen, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Pageof 9